Vmn2r23 Inhibitors
Vmn2r23 inhibitors pertain to a category of chemical agents geared towards the modulation of a specific subset of olfactory receptors. The acronym Vmn2r23 comes from Vomeronasal type-2 receptor, member 23, which is part of a larger family of G protein-coupled receptors (GPCRs) encoded by the Vmn2r genes. These receptors are predominantly expressed in the vomeronasal organ (VNO), an olfactory structure that is critical for pheromone detection in many vertebrates. Unlike the main olfactory system, which typically detects volatile odorants, the VNO is particularly attuned to sensing pheromones, the chemical signals critical for intraspecific communication, often influencing social and reproductive behaviors. The Vmn2r23 receptors are intriguing due to their highly specialized role in the detection of these semiochemicals, which are complex and species-specific.
The inhibitors of Vmn2r23 are specialized molecules that bind to these receptors and block their normal function. The inhibition process is a biochemical interaction where the inhibitor molecule attaches to the receptor, preventing the binding of its natural ligand, and consequently, the receptor's subsequent activation and signal transduction. This interaction is of great interest in the study of chemosensory mechanisms, as it allows researchers to dissect the complex pathways and systems associated with olfactory signal processing. The design of Vmn2r23 inhibitors requires a deep understanding of the molecular structure and function of these receptors, as well as the nature of their ligands. This involves various branches of chemistry, including biochemistry, medicinal chemistry, and organic chemistry, to identify and synthesize molecules that possess the necessary properties to effectively interact with the Vmn2r23 receptor. These inhibitors can be small organic compounds, peptides, or other molecular entities capable of achieving the desired inhibitory effect.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ICI 182,780 | 129453-61-8 | sc-203435 sc-203435A | 1 mg 10 mg | $81.00 $183.00 | 34 | |
Fulvestrant is an estrogen receptor antagonist that directly inhibits the estrogen receptor by degrading it and preventing its activation. Since Vmn2r23 is a vomeronasal receptor that could be indirectly affected by hormone levels, the inhibition of estrogen receptors by Fulvestrant may lead to a decreased functional activity of Vmn2r23 due to altered hormonal signaling. | ||||||
Letrozole | 112809-51-5 | sc-204791 sc-204791A | 25 mg 50 mg | $85.00 $144.00 | 5 | |
Letrozole is an aromatase inhibitor that reduces estrogen synthesis. By decreasing the levels of estrogen, Letrozole indirectly influences hormonal pathways that Vmn2r23 might be responsive to, possibly leading to a reduction in Vmn2r23 activity due to the lowered hormone stimulation. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $256.00 | 18 | |
Tamoxifen is a selective estrogen receptor modulator (SERM) that acts as an antagonist in certain tissues. By blocking estrogen’s effects, Tamoxifen can indirectly decrease the activation of hormonal pathways that may interact with Vmn2r23, hence potentially inhibiting its activity. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $62.00 $260.00 | 21 | |
Ketoconazole is an antifungal agent that also has the ability to inhibit steroid synthesis, including estrogen and testosterone. This can reduce the hormonal activation of pathways that Vmn2r23 may be a part of, leading to a potential inhibition of its functional activity. | ||||||
Flutamide | 13311-84-7 | sc-204757 sc-204757A sc-204757D sc-204757B sc-204757C | 1 g 5 g 25 g 500 g 1 kg | $46.00 $153.00 $168.00 $515.00 $923.00 | 4 | |
Flutamide is a nonsteroidal antiandrogen that blocks androgen receptors. By disrupting androgen receptor signaling, Flutamide could indirectly affect the functional activity of Vmn2r23 if Vmn2r23 is modulated by androgen levels. | ||||||
Bicalutamide | 90357-06-5 | sc-202976 sc-202976A | 100 mg 500 mg | $41.00 $143.00 | 27 | |
Bicalutamide is another nonsteroidal antiandrogen that competitively inhibits androgen receptors. This inhibition could lead to decreased activation of Vmn2r23 by reducing the effects of androgens on signaling pathways that Vmn2r23 may be involved in. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $240.00 $1030.00 | 7 | |
Enzalutamide is a more potent antiandrogen than Flutamide and Bicalutamide and works by blocking androgen receptors. This could result in a decreased functional activity of Vmn2r23 due to the diminished androgen receptor-mediated signaling. | ||||||
Anastrozole | 120511-73-1 | sc-217647 | 10 mg | $90.00 | 1 | |
Anastrozole is an aromatase inhibitor that prevents the conversion of androgens to estrogens, leading to a decrease in estrogen levels. Lower estrogen levels could indirectly inhibit Vmn2r23 activity by affecting hormone-responsive pathways. | ||||||
Exemestane | 107868-30-4 | sc-203045 sc-203045A | 25 mg 100 mg | $131.00 $403.00 | ||
Exemestane is an irreversible steroidal aromatase inhibitor, leading to a significant reduction in estrogen levels. This drop in estrogen could indirectly inhibit Vmn2r23 by lessening hormonal signaling that may affect its function. | ||||||
Finasteride | 98319-26-7 | sc-203954 | 50 mg | $103.00 | 3 | |
Finasteride is a 5-alpha-reductase inhibitor that prevents the conversion of testosterone to dihydrotestosterone (DHT). By altering androgen signaling, Finasteride could indirectly affect Vmn2r23 functional activity if it is responsive to androgen levels. | ||||||